ArticleCureus2026
The Association Between Serum Nesfatin-1 Levels and Metabolic Parameters in Women With Polycystic Ovary Syndrome: A Cross-Sectional Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with metabolic abnormalities such as insulin resistance, obesity, and dyslipidemia. Nesfatin-1, an anorexigenic peptide derived from nucleobindin-2, plays a key role in energy homeostasis and glucose metabolism. However, existing studies report inconsistent findings regarding its levels and metabolic associations in PCOS, and data from small clinical populations remain limited. Hence, this study aimed to evaluate serum nesfatin-1 levels in women with PCOS and examine their association with metabolic and anthropometric parameters, particularly insulin resistance. Methods This cross-sectional study included 50 women aged 18-35 years, comprising 25 women with PCOS diagnosed according to the Rotterdam criteria and 25 age-matched healthy controls. Anthropometric parameters were recorded, and fasting blood glucose, fasting insulin, and serum nesfatin-1 levels were measured using standard biochemical methods and enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed using the independent samples t-test, Pearson correlation, and receiver operating characteristic (ROC) curve analysis. Results Women with PCOS exhibited significantly higher fasting blood glucose and fasting insulin levels and significantly lower serum nesfatin-1 levels compared to controls (p < 0.001). Pearson correlation analysis revealed a strong negative correlation between nesfatin-1 and fasting insulin (r = -0.70, p < 0.001) and a moderate negative correlation with fasting blood glucose (r = -0.48, p < 0.001). No significant correlation was observed between nesfatin-1 and BMI (r = -0.17, p = 0.37). ROC curve analysis demonstrated excellent diagnostic performance of nesfatin-1 (area under the curve (AUC) = 0.96). Conclusions Serum nesfatin-1 levels are markedly lower in women with PCOS and are negatively correlated with markers of insulin resistance. These findings indicate a possible role for nesfatin-1 in metabolic dysregulation in PCOS and underscore its potential as a biomarker, although additional large-scale and longitudinal studies are needed to confirm these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.